Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.

[1]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[2]  C. Serratrice,et al.  Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series , 2015, Journal of Medical Case Reports.

[3]  B. Bembi,et al.  Results from a 9‐year Intensive Safety Surveillance Scheme (IS3) in miglustat (Zavesca®)‐treated patients , 2015, Pharmacoepidemiology and drug safety.

[4]  C. Hollak,et al.  Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. , 2013, Blood cells, molecules & diseases.

[5]  M. Silkey,et al.  Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study , 2012, Orphanet Journal of Rare Diseases.

[6]  C. Hendriksz,et al.  Gastrointestinal disturbances and their management in miglustat-treated patients , 2011, Journal of Inherited Metabolic Disease.

[7]  P. Stein,et al.  Osseous Manifestations of Adult Gaucher Disease in the Era of Enzyme Replacement Therapy , 2011, Medicine.

[8]  C. Niederau,et al.  Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. , 2010, Brain : a journal of neurology.

[9]  A. Bárez,et al.  Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project , 2009, Haematologica.

[10]  B. Bembi,et al.  Miglustat (Zavesca®) in type 1 Gaucher disease: 5‐year results of a post‐authorisation safety surveillance programme , 2009, Pharmacoepidemiology and drug safety.

[11]  A. Mehta,et al.  Goal-oriented therapy with miglustat in Gaucher disease. , 2009, Current medical research and opinion.

[12]  S. van Weely,et al.  Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. , 2007, Blood.

[13]  Joel L Sussman,et al.  Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. , 2007, The Journal of biological chemistry.

[14]  P. Alfonso,et al.  Neurological evaluation of patients with Gaucher disease diagnosed as type 1 , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[15]  G. Pastores,et al.  Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. , 2007, Clinical therapeutics.

[16]  P. Alfonso,et al.  S-MRI score: A simple method for assessing bone marrow involvement in Gaucher disease. , 2007, European journal of radiology.

[17]  O. Morand,et al.  The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  J. Yee,et al.  The long-term international safety experience of imiglucerase therapy for Gaucher disease. , 2007, Molecular genetics and metabolism.

[19]  A. Acedo,et al.  Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease. , 2006, Haematologica.

[20]  S. Othman,et al.  Comparison of bone mineral density with dual energy x-ray absorptiometry, quantitative ultrasound and single energy x-ray absorptiometry. , 2005, Saudi medical journal.

[21]  J. Sancho,et al.  Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. , 2005, Blood cells, molecules & diseases.

[22]  G. Pastores,et al.  An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. , 2005, Clinical therapeutics.

[23]  R. Dwek,et al.  Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease , 2004, Journal of Inherited Metabolic Disease.

[24]  G. Andria,et al.  Therapeutic goals in the treatment of Gaucher disease. , 2004, Seminars in hematology.

[25]  G. Andria,et al.  The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement , 2003, Journal of Inherited Metabolic Disease.

[26]  R. Dwek,et al.  Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis , 2000, The Lancet.

[27]  T. Cox,et al.  3 Gaucher's disease: clinical features and natural history , 1997 .

[28]  T. Cox,et al.  Gaucher's disease: clinical features and natural history. , 1997, Bailliere's clinical haematology.

[29]  M. Itzchaki,et al.  Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. , 1996, Blood cells, molecules & diseases.

[30]  J. Dambrosia,et al.  Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. , 1995, Pediatrics.

[31]  D. Balicki,et al.  The clinical course of treated and untreated Gaucher disease. A study of 45 patients. , 1995, Blood cells, molecules & diseases.

[32]  M. Horowitz,et al.  Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment. , 1994, The American journal of medicine.

[33]  J. Dambrosia,et al.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.